<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Approach to the adult with lymphocytosis or lymphocytopenia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Approach to the adult with lymphocytosis or lymphocytopenia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Approach to the adult with lymphocytosis or lymphocytopenia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Matthew S Davids, MD, MMSc</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter Newburger, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 03, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H330922311"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Lymphocytosis refers to an increase of peripheral blood lymphocytes, which for adults corresponds to &gt;4000 lymphocytes/microL in most clinical laboratories.</p><p>Lymphocytopenia refers to a decrease of peripheral blood lymphocytes, which generally corresponds to &lt;1000 lymphocytes/microL in adults.</p><p>This topic discusses the causes and our approach to clinical evaluation of lymphocytosis and lymphocytopenia in adults. The evaluation and causes of leukocytosis and lymphocytopenia in children are discussed separately. (See  <a class="medical medical_review" href="/d/html/8387.html" rel="external">"Approach to the child with lymphocytosis or lymphocytopenia"</a>.)</p><p class="headingAnchor" id="H1891381287"><span class="h1">DEFINITIONS AND NORMAL VALUES</span><span class="headingEndMark"> — </span>The normal range (ie, two standard deviations above and below the mean) for the white blood cell (WBC) count in adults is 4400 to 11,000 cells/microL in most clinical laboratories. Lymphocytes generally constitute 8 to 33 percent of WBCs in peripheral blood.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Absolute lymphocyte count</strong> – The absolute lymphocyte count (ALC) is used to quantitate lymphocytes in peripheral blood (rather than the percentage of lymphocytes in the WBC differential count).</p><p></p><p class="bulletIndent1">ALC is calculated as follows:</p><p></p><p class="bulletIndent2">ALC (cells/microL) = WBC (cells/microL) x percent lymphocytes ÷ 100</p><p></p><p class="bulletIndent1">Normal values for ALC generally correspond to 1000 to 4000 lymphocytes/microL, but may vary in different laboratories.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lymphocytosis</strong> corresponds to ALC &gt;4000 cells/microL for adults.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lymphocytopenia</strong> corresponds to ALC &lt;1000 cells/microL for adults.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lymphocyte subsets</strong> – Normal proportions of T lymphocytes, B lymphocytes, and natural killer (NK) cells in the peripheral blood are:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>T cells (CD3+) – 60 to 80 percent</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>B cells (CD20+) – 10 to 20 percent</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>NK cells (CD56+) – 5 to 10 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>T lymphocyte subtypes</strong> – Normal proportions of T cell subtypes in peripheral blood are:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Helper/inducer T cells (CD4+) – 60 to 70 percent</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Suppressor/cytotoxic T cells (CD8+) – 30 to 40 percent</p><p></p><p class="bulletIndent1">Normal values for WBC and lymphocyte counts in children vary by age and are discussed separately. (See  <a class="medical medical_review" href="/d/html/8387.html" rel="external">"Approach to the child with lymphocytosis or lymphocytopenia"</a>.)</p><p></p><p class="headingAnchor" id="H1031225720"><span class="h1">MECHANISMS</span><span class="headingEndMark"> — </span>Lymphocyte differentiation and maturation are life-long processes that take place in the bone marrow and secondary lymphoid organs (eg, lymph nodes, spleen, thymus). Details of lymphocyte development are discussed separately. (See  <a class="medical medical_review" href="/d/html/13933.html" rel="external">"Normal B and T lymphocyte development"</a>.)</p><p>Lymphocytosis may be caused by increased production, redistribution (from bone marrow and/or secondary lymphoid organs), and/or decreased cell death (eg, from impaired apoptosis in some lymphoproliferative disorders). Various causes of lymphocytosis differ in the contribution from each of these mechanisms.</p><p>Increased lymphocyte production may be due to a malignant process or in response to an infectious or inflammatory stimulus. Malignant lymphocytosis involves expansion of a clone of related cells, whereas reactive processes generally reflect polyclonal expansion of lymphocytes. Reactive processes may lead to expansion of one or more subsets of lymphocytes (ie, T cells, B cells, and/or NK cells).</p><p class="headingAnchor" id="H2705667192"><span class="h1">CAUSES OF LYMPHOCYTOSIS</span></p><p class="headingAnchor" id="H1692569306"><span class="h2">Infectious causes</span><span class="headingEndMark"> — </span>Specific infectious causes of reactive lymphocytosis vary depending on demographic characteristics of the population. As examples, the incidence of certain infections varies based on geography, and infectious mononucleosis is more common in young adults.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infectious mononucleosis</strong> (IM) is a viral infection characterized by fever, tonsillar pharyngitis, and lymphadenopathy. Lymphocytosis is the most common hematologic manifestation of IM, and lymphocytes may constitute more than half of circulating leukocytes. The peripheral blood smear usually contains reactive "atypical" lymphocytes  (<a class="graphic graphic_picture graphicRef55986" href="/d/graphic/55986.html" rel="external">picture 1</a>) that peak during the second and third week of illness and may persist for up to two months [<a href="#rid1">1</a>]. (See <a class="local">'Peripheral blood smear'</a> below.)</p><p></p><p class="bulletIndent1">IM is most often caused by infection with Epstein-Barr virus (EBV). IM may also be associated with other hematologic findings, including hemolytic anemia and thrombocytopenia. (See  <a class="medical medical_review" href="/d/html/8318.html" rel="external">"Infectious mononucleosis", section on 'Hematologic abnormalities'</a>.)</p><p></p><p class="bulletIndent1">Other infectious agents can cause a nearly indistinguishable IM syndrome including cytomegalovirus (CMV), human immunodeficiency virus (HIV), other viruses, and toxoplasmosis. (See  <a class="medical medical_review" href="/d/html/8318.html" rel="external">"Infectious mononucleosis", section on 'EBV-negative mononucleosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other viral illnesses</strong> that can be associated with lymphocytosis include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>HIV</p><p class="bulletIndent2"><span class="glyph">•</span>HTLV-I (human T-lymphotropic virus type I)</p><p class="bulletIndent2"><span class="glyph">•</span>CMV</p><p class="bulletIndent2"><span class="glyph">•</span>Mumps</p><p class="bulletIndent2"><span class="glyph">•</span>Rubella</p><p class="bulletIndent2"><span class="glyph">•</span>Measles</p><p class="bulletIndent2"><span class="glyph">•</span>Influenza</p><p class="bulletIndent2"><span class="glyph">•</span>Hepatitis</p><p class="bulletIndent2"><span class="glyph">•</span>Adenovirus</p><p class="bulletIndent2"><span class="glyph">•</span>Coxsackie virus</p><p class="bulletIndent2"><span class="glyph">•</span>Poliovirus</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pertussis</strong> – Pertussis (whooping cough) is a respiratory infection caused by <em>Bordetella pertussis </em>infection. Unlike most other acute bacterial infections, pertussis commonly causes lymphocytosis. The lymphocytes in pertussis often have a characteristic appearance with a convoluted and/or cleaved nucleus  (<a class="graphic graphic_picture graphicRef115806" href="/d/graphic/115806.html" rel="external">picture 2</a>). Clinical manifestations and diagnosis of pertussis are described separately. (See  <a class="medical medical_review" href="/d/html/8045.html" rel="external">"Pertussis infection in adolescents and adults: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1">Lymphocytosis appears to be specific to <em>B. pertussis </em>infection, since it is not seen with a clinically identical illness caused by <em>B. parapertussis</em>. As an example, in one study of 114 patients the mean absolute lymphocyte count (ALC) was significantly lower in those infected with <em>B. parapertussis</em> than in those with <em>B. pertussis</em> (3500 versus 7800/microL, respectively) [<a href="#rid2">2</a>]. Because both <em>B. pertussis</em> and <em>B. parapertussis</em> express pertussis toxin, some other effect of <em>B. pertussis</em> must account for the lymphocytosis.</p><p></p><p class="bulletIndent1">The lymphocytosis in pertussis is polyclonal with a normal T:B lymphocyte ratio and appears to be due to a block in extravasation of lymphocytes from the blood into lymph nodes, rather than an increase in lymphocyte production [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cat scratch disease </strong>– Cat scratch disease is an infection with <em>Bartonella henselae </em>that manifests as lymphadenopathy and can be associated with neurologic, ocular, and other organ involvement. The lymphocytosis usually includes large atypical lymphocytes and may be accompanied by mild eosinophilia, monocytosis, anemia, and/or thrombocytopenia [<a href="#rid4">4</a>]. Details of the clinical presentation and diagnosis of cat scratch disease are discussed separately. (See  <a class="medical medical_review" href="/d/html/5532.html" rel="external">"Microbiology, epidemiology, clinical manifestations, and diagnosis of cat scratch disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other infectious causes </strong>– Infections such as tuberculosis, brucellosis, syphilis, babesiosis, and rickettsial infections may present a similar hematologic picture. </p><p></p><p class="headingAnchor" id="H3707269253"><span class="h2">Non-infectious causes</span></p><p class="headingAnchor" id="H1443801887"><span class="h3">Drug hypersensitivity reactions</span><span class="headingEndMark"> — </span>Drug reaction with eosinophilia and systemic symptoms (DRESS) is an allergic/hypersensitivity reaction to a medication. DRESS usually occurs two to six weeks after starting the offending drug. Lymphocytosis (eg, in the range of 10,000/microL) with atypical lymphocytes and eosinophilia is seen in 30 to 70 percent of cases of DRESS [<a href="#rid5">5</a>]. Additional details are presented separately  (<a class="graphic graphic_table graphicRef86760" href="/d/graphic/86760.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/16420.html" rel="external">"Drug reaction with eosinophilia and systemic symptoms (DRESS)"</a> and  <a class="medical medical_review" href="/d/html/2086.html" rel="external">"Drug hypersensitivity: Classification and clinical features"</a>.)</p><p class="headingAnchor" id="H1909659640"><span class="h3">Stress</span><span class="headingEndMark"> — </span>Lymphocytosis can be associated with severe medical stress, including trauma, cardiac emergencies, or status epilepticus. A study of 73 adults (age 43 to 93 years) with such conditions reported ALCs from 4000 to 13,000/microL that was often followed by neutrophilia [<a href="#rid6">6</a>]. Lymphocytosis in this setting has been associated with mortality rates of 25 to 50 percent [<a href="#rid6">6,7</a>].</p><p class="headingAnchor" id="H3698562569"><span class="h3">Persistent polyclonal B cell lymphocytosis</span><span class="headingEndMark"> — </span>A syndrome of persistent polyclonal B cell lymphocytosis (PPBL) has been described in young to middle-aged women who smoke cigarettes. The syndrome includes polyclonal B cell expansion, a polyclonal increase in serum IgM, and may be accompanied by splenomegaly and/or lymphadenopathy [<a href="#rid8">8-12</a>]. The median ALC is 5500 cells/microL (range 2000 to 21,000 cells/microL) with characteristic binucleate lymphocytes  (<a class="graphic graphic_picture graphicRef116325" href="/d/graphic/116325.html" rel="external">picture 3</a>).</p><p>Despite the presence of cytogenetic anomalies in most patients (eg, isochromosome 3q, <em>BCL2/</em>immunoglobulin gene rearrangements), the clinical course typically remains stable for years. As an example, a study of more than 100 patients reported 89 percent four-year event-free survival [<a href="#rid13">13,14</a>]. </p><p>The pathogenesis of PPBL is not known. Potential mechanisms include a defect in the CD40 activation pathway, expansion of functional IgD+ CD27+ memory B cells, or undefined genetic defects [<a href="#rid15">15-19</a>]. </p><p class="headingAnchor" id="H992688327"><span class="h3">Asplenia</span><span class="headingEndMark"> — </span>Moderate levels of polyclonal lymphocytosis are common after splenectomy. Most patients with post-splenectomy lymphocytosis have large granular lymphocytes on the peripheral smear and expansion of NK cells [<a href="#rid20">20,21</a>]. In one series, 20 of 23 patients who underwent splenectomy (most for Hodgkin lymphoma) had lymphocyte counts from 4000 to 8700/microL; lymphocytosis persisted almost unchanged with median follow-up of more than four years [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H219026063"><span class="h3">Thymoma</span><span class="headingEndMark"> — </span>Thymoma is a thymic malignancy that typically affects middle-aged adults and may be associated with paraneoplastic autoimmune syndromes (eg, myasthenia gravis, pure red cell aplasia). Thymoma is occasionally associated with polyclonal T cell lymphocytosis that can range from 6900 to 24,000/microL and resolves following successful treatment of the tumor [<a href="#rid22">22-25</a>]. The cause of the lymphocytosis is unclear, but the circulating lymphocytes appear normal by morphology, immunophenotyping, and T cell receptor gene rearrangement studies [<a href="#rid23">23</a>]. Further description of clinical aspects of thymoma is provided separately. (See  <a class="medical medical_review" href="/d/html/4619.html" rel="external">"Clinical presentation and management of thymoma and thymic carcinoma"</a>.)</p><p class="headingAnchor" id="H1516036561"><span class="h2">Clonal processes</span><span class="headingEndMark"> — </span>Causes of clonal lymphocytosis exist on a spectrum and range from premalignant disorders (that may later evolve to overt malignancies) to a variety of lymphomas and leukemias.</p><p class="headingAnchor" id="H1359939611"><span class="h3">Monoclonal B lymphocytosis</span><span class="headingEndMark"> — </span>Monoclonal B cell lymphocytosis (MBL) refers to a monoclonal population of B lymphocytes &lt;5000 cells/microL in peripheral blood (ie, below the threshold for diagnosis of chronic lymphocytic leukemia [CLL]), without associated clinical findings of an autoimmune condition, infectious disease, or lymphoproliferative disorder (eg, no lymphadenopathy, hepatosplenomegaly, cytopenias, fever, weight loss, or sweats). B cell clonality may be detected in some individuals with &lt;4000 lymphocytes/microL (ie, the threshold for defining lymphocytosis).</p><p>Most patients with MBL have an immunophenotype that is indistinguishable from CLL, while other cases have an atypical or non-CLL-like immunophenotype. Epidemiology, diagnosis, classification, prognosis, and management of MBL are discussed separately. (See  <a class="medical medical_review" href="/d/html/118011.html" rel="external">"Monoclonal B cell lymphocytosis"</a>.)</p><p class="headingAnchor" id="H1951432233"><span class="h3">Congenital B cell lymphocytosis</span><span class="headingEndMark"> — </span>Congenital B cell lymphocytosis is a rare familial syndrome in which infants present with splenomegaly and polyclonal expansion of B cells that progresses to CLL by the fourth decade of life [<a href="#rid26">26</a>].</p><p>Affected patients have mutations of <em>CARD11</em>, which encodes a protein (caspase recruitment domain-containing protein 11) required for nuclear factor-kappa B activation of B and T lymphocytes. CARD11 deficiency syndrome is described separately. (See  <a class="medical medical_review" href="/d/html/3914.html" rel="external">"Primary humoral immunodeficiencies: An overview", section on 'Isotype, light chain, or functional deficiencies with generally normal numbers of B cells'</a>.)</p><p class="headingAnchor" id="H2679685677"><span class="h3">Large granular lymphocyte leukemia</span><span class="headingEndMark"> — </span>Large granular lymphocyte (LGL) leukemia is characterized by infiltration of peripheral blood and bone marrow by clonal LGLs, splenomegaly, and cytopenias (usually neutropenia). Patients typically present in the fourth or fifth decade of life with autoimmune manifestations and neutropenia. The blood smear characteristically reveals large lymphocytes with slightly eccentric nuclei, abundant pale-blue cytoplasm, and azurophilic granules  (<a class="graphic graphic_picture graphicRef69027" href="/d/graphic/69027.html" rel="external">picture 4</a>) at levels &gt;2000 cells/microL; some patients have a normal ALC with an increased percentage of cytotoxic (CD8+) lymphocytes [<a href="#rid27">27-29</a>].</p><p>Details of the clinical presentation and diagnosis of LGL leukemia are discussed separately. (See  <a class="medical medical_review" href="/d/html/4538.html" rel="external">"Natural killer (NK) cell large granular lymphocyte leukemia"</a>.)</p><p class="headingAnchor" id="H1616252797"><span class="h3">Chronic lymphocytic leukemia</span><span class="headingEndMark"> — </span>Chronic lymphocytic leukemia (CLL) is a chronic lymphoproliferative neoplasm characterized by progressive accumulation in peripheral blood and bone marrow of lymphocytes that may be accompanied by lymphadenopathy, splenomegaly, and/or constitutional symptoms. CLL is defined by the presence of ≥5000 lymphocytes/microL. The leukemic cells are typically small and mature-appearing with a dense nucleus, partially clumped chromatin, no discernible nucleoli, and a thin border of clear or slightly basophilic cytoplasm. Some of the lymphocytes may be larger with a notched nucleus, lacy-appearing chromatin, and prominent visible nucleoli (so-called prolymphocytes). The smear typically contains characteristic "smudge" cells that appear to have been damaged when smeared on a glass slide  (<a class="graphic graphic_picture graphicRef96498" href="/d/graphic/96498.html" rel="external">picture 5</a>).</p><p>Clinical manifestations, pathologic features, and diagnosis of CLL are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/4513.html" rel="external">"Clinical features and diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma"</a>.)</p><p class="headingAnchor" id="H3993973188"><span class="h3">Non-Hodgkin lymphoma</span><span class="headingEndMark"> — </span>Most categories of non-Hodgkin lymphoma (NHL) can be associated with lymphocytosis, but certain subtypes are more likely:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sézary syndrome</strong>, which is defined by the presence of circulating malignant T lymphocytes; details of clinical manifestations and diagnosis are presented separately. (See  <a class="medical medical_review" href="/d/html/16193.html" rel="external">"Clinical presentation, pathologic features, and diagnosis of Sézary syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mantle cell lymphoma</strong> (MCL) has the highest prevalence of lymphocytosis among B cell lymphomas; about one half of patients with MCL have lymphocytosis. Additional details are presented separately. (See  <a class="medical medical_review" href="/d/html/4702.html" rel="external">"Mantle cell lymphoma: Epidemiology, pathobiology, clinical manifestations, diagnosis, and prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follicular lymphoma </strong>and<strong> splenic marginal zone lymphoma </strong>are often associated with lymphocytosis. (See  <a class="medical medical_review" href="/d/html/4699.html" rel="external">"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma"</a> and  <a class="medical medical_review" href="/d/html/4731.html" rel="external">"Splenic marginal zone lymphoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Subtypes of NHL less commonly associated with lymphocytosis include diffuse large B cell lymphoma, Burkitt lymphoma, and T cell lymphoma other than Sézary syndrome. (See  <a class="medical medical_review" href="/d/html/4703.html" rel="external">"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma"</a> and  <a class="medical medical_review" href="/d/html/4700.html" rel="external">"Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma"</a> and  <a class="medical medical_review" href="/d/html/4694.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified"</a>.)</p><p></p><p>The morphologic appearance and immunophenotype of circulating lymphocytes depends on the subtype of underlying NHL.</p><p class="headingAnchor" id="H2376257218"><span class="h3">Acute lymphoblastic leukemia</span><span class="headingEndMark"> — </span>Acute lymphoblastic leukemia (ALL) may be derived from T, B, or NK cells, and can present at any age. Lymphoblasts vary from small cells with scant cytoplasm, condensed nuclear chromatin, and indistinct nucleoli to larger cells with moderate amounts of cytoplasm, dispersed chromatin, and multiple nucleoli; a few azurophilic cytoplasmic granules may be present. Typical presenting symptoms are nonspecific and may include symptoms of cytopenias, fever, bone pain, lymphadenopathy, organomegaly, and/or mediastinal mass. The immunophenotype varies depending on the lineage of the leukemic cells (eg, B versus T lineage).</p><p>Details of the clinical presentation and diagnosis of B cell ALL and T cell leukemia/lymphoma in adults are discussed separately (See  <a class="medical medical_review" href="/d/html/4686.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of B cell acute lymphoblastic leukemia/lymphoma"</a> and  <a class="medical medical_review" href="/d/html/15773.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma"</a>.)</p><p class="headingAnchor" id="H814303532"><span class="h1">EVALUATION</span></p><p class="headingAnchor" id="H1463539878"><span class="h2">Urgency of evaluation</span><span class="headingEndMark"> — </span>The urgency of evaluation of lymphocytosis is guided by the patient's clinical condition, the degree and rate of rise of lymphocytosis (if known), and worrisome findings (eg, leukemic blasts) on the blood smear.</p><p>As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Lymphocytosis accompanied by hemodynamic instability, respiratory compromise, or other clinical emergency requires immediate hospitalization and urgent evaluation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Asymptomatic lymphocytosis without worrisome findings on blood smear or blood chemistries may be evaluated as an outpatient. (See <a class="local">'Peripheral blood smear'</a> below.)</p><p></p><p>No specific level of lymphocytosis constitutes a medical emergency. The response to marked lymphocytosis is influenced by whether a diagnosis has previously been established.</p><p>As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>If the cause of lymphocytosis is <strong>not</strong> known, an absolute lymphocyte count (ALC) &gt;50,000 cells/microL may require prompt evaluation and hematology consultation to make an initial assessment about the urgency of further testing. (See  <a class="medical medical_review" href="/d/html/8381.html" rel="external">"Approach to the patient with neutrophilia", section on 'Leukemoid reaction/hyperleukocytosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Conversely, an asymptomatic, clinically stable patient with documented chronic lymphocytic leukemia (CLL) does not require urgent hematologic consultation based on elevated ALC alone; a patient with documented CLL may remain asymptomatic and clinically stable irrespective of the degree of lymphocytosis. </p><p></p><p class="headingAnchor" id="H1561988821"><span class="h2">Initial evaluation</span><span class="headingEndMark"> — </span>Lymphocytosis may be encountered in the course of evaluating other clinical findings or as an incidental abnormality on a complete blood count (CBC) and differential.</p><p>Initial evaluation of lymphocytosis includes CBC, history and physical examination, and review of the blood smear.</p><p>The initial evaluation of lymphocytosis cannot determine clonality or the subtype of lymphocytes (ie, B versus T versus NK cells); such conclusions require flow cytometry or other specialized tests, as described below. (See <a class="local">'Distinguishing clonal versus polyclonal processes'</a> below.)</p><p class="headingAnchor" id="H1919057392"><span class="h3">Complete blood count (CBC)</span><span class="headingEndMark"> — </span>The abnormal CBC and differential count should be repeated to exclude laboratory error:</p><p class="bulletIndent1"><span class="glyph">●</span>Repeat CBC should be performed immediately if the patient is clinically unstable, worrisome findings are reported (eg, leukemic blasts), or ALC is markedly elevated (eg, &gt;30,000 cells/microL) without a known diagnosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The CBC can be repeated with less urgency (eg, within one to two weeks) if the patient is clinically stable, the lymphocytosis is modest, and no worrisome findings are reported on blood smear.</p><p></p><p>When available, prior CBCs (both normal and abnormal) can provide important information about the duration and trajectory of lymphocytosis.</p><p>ALCs can rise to 20,000 to 30,000 cells/microL in reactive lymphocytoses (eg, infection or inflammation). The higher the ALC is above these values, the lower is the likelihood of a reactive disorder. That is, the likelihood of a malignant disorder increases with ALC &gt;30,000/microL and/or characteristic findings on the blood smear (eg, lymphoblasts, smudge cells). (See <a class="local">'Peripheral blood smear'</a> below.)</p><p>In general, reactive lymphocytosis can be expected to persist while the underlying inflammatory/infectious process is active. Lymphocytosis caused by an acute condition (eg, infection) should resolve within one to two months; a longer duration of lymphocytosis might raise concerns regarding an underlying malignant process.</p><p>Lymphocytosis may be the sole abnormality in the CBC and blood smear, or it may be accompanied by other blood abnormalities, including:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increased eosinophils or basophils</strong> accompanying lymphocytosis may be due to:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Allergic conditions or medications (see <a class="local">'Drug hypersensitivity reactions'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Infections (see <a class="local">'Infectious causes'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Inflammatory conditions (see <a class="local">'Non-infectious causes'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increased neutrophils and/or monocytes </strong>accompanying lymphocytosis may be due to:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Infections (see <a class="local">'Infectious causes'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Inflammatory conditions (see <a class="local">'Non-infectious causes'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Medications (see <a class="local">'Drug hypersensitivity reactions'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Severe medical stress or other conditions (eg, asplenia) (see <a class="local">'Non-infectious causes'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anemia </strong>– Anemia associated with lymphocytosis can have varied causes. Examples include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hemolytic anemia or pure red cell aplasia associated with CLL or large granular lymphocyte leukemia (see  <a class="medical medical_review" href="/d/html/4513.html" rel="external">"Clinical features and diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma", section on 'Cytopenias'</a> and  <a class="medical medical_review" href="/d/html/16360.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of T cell large granular lymphocyte leukemia", section on 'Clinical features'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Anemia of chronic disease associated with chronic inflammatory conditions or infections (see  <a class="medical medical_review" href="/d/html/7149.html" rel="external">"Anemia of chronic disease/anemia of inflammation"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bone marrow infiltration by various leukemias and infections</p><p></p><p class="bulletIndent1">Clinical evaluation of anemia is discussed in greater detail separately (see  <a class="medical medical_review" href="/d/html/7133.html" rel="external">"Diagnostic approach to anemia in adults"</a>)  </p><p></p><p class="headingAnchor" id="H1556973766"><span class="h3">History and physical examination</span><span class="headingEndMark"> — </span>The history should seek evidence of disorders that might account for lymphocytosis. (See <a class="local">'Causes of lymphocytosis'</a> above.)</p><p>Important aspects of the history include evidence of:</p><p class="bulletIndent1"><span class="glyph">●</span>Active or prior infection or inflammatory processes (eg, trauma, seizure, arthritis, rash). (See <a class="local">'Causes of lymphocytosis'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Previously diagnosed hematologic malignancy (eg, lymphoma, leukemia) or related symptoms and/or signs (eg, unexplained lymphadenopathy, fevers, sweats, weight loss). (See <a class="local">'Clonal processes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Surgical or functional asplenia. (See <a class="local">'Asplenia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medications, including the association between the onset of lymphocytosis (if known) and onset of drugs associated with drug reaction with eosinophilia and systemic symptoms (DRESS)  (<a class="graphic graphic_table graphicRef86760" href="/d/graphic/86760.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/16420.html" rel="external">"Drug reaction with eosinophilia and systemic symptoms (DRESS)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cigarette smoking. (See <a class="local">'Persistent polyclonal B cell lymphocytosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Family history of lymphoid neoplasms or lymphocytosis. (See <a class="local">'Monoclonal B lymphocytosis'</a> above.)</p><p></p><p>Physical examination should seek evidence of infection, inflammation, or malignancy, such as fever, lymphadenopathy, hepatosplenomegaly, joint redness, abdominal pain, and lung findings.</p><p>The presence of lymphadenopathy and/or splenomegaly does not indicate whether the lymphocytosis is malignant versus reactive (ie, infectious or non-infectious) because those clinical findings can be associated with either category of disease.</p><p class="headingAnchor" id="H4177589950"><span class="h3">Peripheral blood smear</span><span class="headingEndMark"> — </span>The peripheral blood smear should be reviewed to assess lymphocyte morphology and detect other hematologic findings.</p><p>Examples of lymphocyte findings on the blood smear include:</p><p class="bulletIndent1"><span class="glyph">●</span>Normal-appearing small lymphocytes may be seen with certain infections (eg, pertussis), CLL, monoclonal B cell lymphocytosis, and other disorders.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Atypical lymphocytes (ie, large lymphocytes with abundant basophilic cytoplasm and a large, irregularly shaped nucleus that may exhibit nucleoli)  (<a class="graphic graphic_picture graphicRef55986" href="/d/graphic/55986.html" rel="external">picture 1</a>) are often seen in infectious mononucleosis and other viral illnesses  (<a class="graphic graphic_table graphicRef58246" href="/d/graphic/58246.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Binucleate lymphocytes are characteristic of persistent polyclonal B cell lymphocytosis (PPBL). (See <a class="local">'Persistent polyclonal B cell lymphocytosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Normal maturing B lymphocyte precursors (so-called "hematogones") can be mistaken for lymphoblasts and represent 0.01 to 1.3 percent of leukocytes in adults, as detected by sensitive flow cytometry methods [<a href="#rid30">30-32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Distinctive lymphoid forms may be seen in certain malignant disorders, including:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>"Smudge" lymphocytes  (<a class="graphic graphic_picture graphicRef54469" href="/d/graphic/54469.html" rel="external">picture 6</a>) are characteristic (but not diagnostic) of CLL. (See  <a class="medical medical_review" href="/d/html/4513.html" rel="external">"Clinical features and diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma", section on 'Peripheral smear'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Villous projections  (<a class="graphic graphic_picture graphicRef59065" href="/d/graphic/59065.html" rel="external">picture 7</a>) may be seen with splenic marginal zone lymphoma. (See  <a class="medical medical_review" href="/d/html/4731.html" rel="external">"Splenic marginal zone lymphoma", section on 'Morphology'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>"Hair-like" projections  (<a class="graphic graphic_picture graphicRef102936" href="/d/graphic/102936.html" rel="external">picture 8</a>) are seen in hairy cell leukemia. (See  <a class="medical medical_review" href="/d/html/4532.html" rel="external">"Clinical features and diagnosis of hairy cell leukemia", section on 'Morphology'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Small lymphocytes with cleaved nuclei  (<a class="graphic graphic_picture graphicRef65023" href="/d/graphic/65023.html" rel="external">picture 9</a>) may be seen with follicular lymphoma and mantle cell lymphoma. (See  <a class="medical medical_review" href="/d/html/4699.html" rel="external">"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma", section on 'Blood and bone marrow'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lymphocytes with "cerebriform" nuclei (ie, Sézary cells)  (<a class="graphic graphic_picture graphicRef70592" href="/d/graphic/70592.html" rel="external">picture 10</a>) are seen in Sézary syndrome/mycosis fungoides. (See  <a class="medical medical_review" href="/d/html/1674.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides", section on 'Circulating Sézary cells'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lymphocytes with azurophilic granules  (<a class="graphic graphic_picture graphicRef69027" href="/d/graphic/69027.html" rel="external">picture 4</a>) may be seen in large granular lymphocyte leukemia. (See  <a class="medical medical_review" href="/d/html/16360.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of T cell large granular lymphocyte leukemia", section on 'Peripheral blood'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lymphoblasts can vary from cells with little cytoplasm  (<a class="graphic graphic_picture graphicRef57831" href="/d/graphic/57831.html" rel="external">picture 11</a>) to abundant bluish cytoplasm or deep blue cytoplasm  (<a class="graphic graphic_picture graphicRef57366" href="/d/graphic/57366.html" rel="external">picture 12</a>) in acute lymphoblastic leukemia (ALL). (See  <a class="medical medical_review" href="/d/html/4686.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of B cell acute lymphoblastic leukemia/lymphoma"</a>.)</p><p></p><p class="headingAnchor" id="H1108550043"><span class="h3">Other laboratory tests</span><span class="headingEndMark"> — </span>Other laboratory tests may be included in the initial evaluation to help distinguish malignant disorders from reactive causes of lymphocytosis and/or identify associated clinical findings or complications include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kidney and liver function tests</strong> may identify associated medical conditions or complications (eg, acute kidney injury due to tumor lysis syndrome associated with ALL).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)</strong> are elevated in inflammation and infection, and may be helpful in evaluating the cause of lymphocytosis; as an example, elevated ESR and/or CRP in an asymptomatic patient may suggest an underlying inflammatory condition.</p><p></p><p class="headingAnchor" id="H2239204061"><span class="h1">ASSESSMENT OF CLONALITY</span></p><p class="headingAnchor" id="H2808185909"><span class="h2">Distinguishing clonal versus polyclonal processes</span><span class="headingEndMark"> — </span>Distinguishing clonal from polyclonal processes is often an important step in determining the cause of lymphocytosis. Clonality cannot be determined by the initial evaluation (ie, history, physical examination, complete blood count [CBC], and blood smear).</p><p>For most patients, flow cytometry is the preferred initial technique to define clonality, as described below. (See <a class="local">'Selection of specialized tests'</a> below.)</p><p>While all malignant lymphocytosis is clonal, not all clonal expansions are malignant; some infectious or inflammatory causes of lymphocytosis may be associated with oligoclonal expansion of lymphocytes (eg, two to five distinct low-abundance clones).</p><p>Conversely, premalignant disorders (eg, monoclonal B lymphocytosis) or early stages of some leukemias may exhibit only low levels of clonal lymphocytes among a larger population of normal polyclonal lymphocytes; in such cases, the diagnosis may only be revealed with follow up (eg, clinical observation, serial CBCs, and/or repeat flow cytometry or molecular testing).</p><p class="headingAnchor" id="H2102219497"><span class="h2">Which patients require flow cytometry?</span><span class="headingEndMark"> — </span>Flow cytometry should <strong>not</strong> be performed in all patients with lymphocytosis.</p><p>A decision to perform flow cytometry and the urgency of testing are informed by the patient's clinical status, the level of lymphocytosis and its trajectory (if known), worrisome findings on blood smear, and clinician and/or patient concern.</p><p>Flow cytometry should be performed promptly when there is:</p><p class="bulletIndent1"><span class="glyph">●</span>Suspicion for acute leukemia (eg, lymphoblasts on blood smear) (see <a class="local">'Peripheral blood smear'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Absolute lymphocyte count (ALC) &gt;30,000 cells/microL without a known diagnosis</p><p></p><p>In less urgent settings, our approach is to repeat the CBC and differential in one to two weeks. We perform flow cytometry of peripheral blood to assess clonality and immunophenotype for the following findings:</p><p class="bulletIndent1"><span class="glyph">●</span>ALC &gt;5000 cells/microL, unless lymphocytosis can be accounted for by evidence of a recent viral infection, offending drug, or asplenia</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Unexplained ALC &gt;4000 cells/microL for &gt;1 month</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rising ALC</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lymphocyte morphology suggestive of malignancy (eg, lymphoblasts, smudge cells, hairy cells) (see <a class="local">'Peripheral blood smear'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cytopenias</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hepatosplenomegaly</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lymphadenopathy</p><p></p><p class="headingAnchor" id="H2916269538"><span class="h2">Selection of specialized tests</span><span class="headingEndMark"> — </span>Selection of specialized tests is informed by the nature of the clinical questions, the urgency of testing, and the specimens that are available.</p><p>In general, flow cytometry of peripheral blood is the preferred initial test for determining clonality in the patient with lymphocytosis. Compared with other specialized techniques (eg, chromosome analysis, molecular/genetic testing), flow cytometry provides more rapid and cost-effective results, and it can also define lymphocyte lineage. (See <a class="local">'Definitions and normal values'</a> above.)</p><p>In some cases, flow cytometry of peripheral blood may not be necessary in a patient with lymphocytosis. If clonality was already defined by other techniques (eg, immunohistochemistry of a lymph node, molecular testing of a bone marrow specimen), flow cytometry of peripheral blood generally does not need to be performed. </p><p class="headingAnchor" id="H78181183"><span class="h2">Specialized tests for clonality</span></p><p class="headingAnchor" id="H2850349690"><span class="h3">Flow cytometry</span><span class="headingEndMark"> — </span>Flow cytometry can define clonality and determine the lineage and immunophenotype of lymphocytes.</p><p>Our approach to deciding when and for whom to perform flow cytometry for evaluation of lymphocytosis is described above. (See <a class="local">'Which patients require flow cytometry?'</a> above.)</p><p>Use of flow cytometry for characterizing lymphocytes is described separately. (See  <a class="medical medical_review" href="/d/html/3937.html" rel="external">"Flow cytometry for the diagnosis of inborn errors of immunity", section on 'Technical aspects'</a> and  <a class="medical medical_review" href="/d/html/4499.html" rel="external">"Detection of measurable residual disease in acute lymphoblastic leukemia/lymphoblastic lymphoma", section on 'Flow cytometry'</a>.)</p><p class="headingAnchor" id="H1839956429"><span class="h3">Molecular/Genetic testing</span><span class="headingEndMark"> — </span>Molecular techniques that can detect clonal populations of lymphocytes include polymerase chain reaction (PCR) and DNA sequencing. </p><p>These techniques can demonstrate the presence of a dominant clone of cells based on rearrangements of either immunoglobulin genes (in B lymphocyte) or T cell receptor genes (in T cells). NK cells are not amenable to such testing, but clonal integration of Epstein-Barr virus (EBV) may be detected in some cases [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/d/html/4538.html" rel="external">"Natural killer (NK) cell large granular lymphocyte leukemia", section on 'Laboratory findings'</a>.)</p><p>Additional aspects of PCR and DNA sequencing are provided separately. (See  <a class="medical medical_review" href="/d/html/2896.html" rel="external">"Polymerase chain reaction (PCR)"</a> and  <a class="medical medical_review" href="/d/html/17039.html" rel="external">"Next-generation DNA sequencing (NGS): Principles and clinical applications"</a>.)</p><p class="headingAnchor" id="H2981944586"><span class="h3">Chromosome analysis</span><span class="headingEndMark"> — </span>Chromosome analysis by conventional karyotype or fluorescence in situ hybridization can identify acquired and inherited causes of lymphocytosis, especially in certain lymphoid leukemias and lymphomas.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>FISH</strong> – Fluorescence in situ hybridization (FISH) on peripheral blood, bone marrow, or lymph nodes can help to define the category of malignant lymphocytosis.</p><p></p><p class="bulletIndent1">FISH is particularly important in diagnosing clonal disorders that are not definitively identified based on morphology and immunophenotype. One important example is the t(11;14) probe for <em>CCND1/IgH</em>, which is positive in mantle cell lymphoma (MCL) and negative in other lymphoid malignancies. (See  <a class="medical medical_review" href="/d/html/2893.html" rel="external">"Tools for genetics and genomics: Cytogenetics and molecular genetics", section on 'Fluorescence in situ hybridization'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Karyotype</strong> – An abnormal karyotype is seen in some cases of adult ALL, CLL, MCL, and other hematologic malignancies. Additional description is provided separately. (See  <a class="medical medical_review" href="/d/html/4484.html" rel="external">"Classification, cytogenetics, and molecular genetics of acute lymphoblastic leukemia/lymphoma"</a> and  <a class="medical medical_review" href="/d/html/4482.html" rel="external">"General aspects of cytogenetic analysis in hematologic malignancies"</a>.)</p><p></p><p class="headingAnchor" id="H330925166"><span class="h1">LYMPHOCYTOPENIA</span><span class="headingEndMark"> — </span>Lymphocytopenia refers to an absolute lymphocyte count (ALC) below a lower threshold, which differs by age. (See <a class="local">'Definitions and normal values'</a> above.)</p><p class="headingAnchor" id="H330925184"><span class="h2">Causes and evaluation</span><span class="headingEndMark"> — </span>Lymphocytopenia may be caused by many conditions  (<a class="graphic graphic_table graphicRef58469" href="/d/graphic/58469.html" rel="external">table 3</a>). Examples include viral infections, such as human immunodeficiency virus (HIV), influenza, coronaviruses (eg, SARS, SARS-CoV-2), hepatitis, measles; bacterial, mycobacterial, fungal, and parasitic infections; protein-energy undernutrition; systemic diseases; congenital immunodeficiency disorders, such as common variable immunodeficiency; and chemotherapy or immunosuppressive therapy, including glucocorticoids.</p><p>The history and physical examination should seek evidence of recent viral or other infections, document medications and possible nutritional deficiencies, and underlying systemic disorders. The severity and duration of lymphocytopenia should be documented, if possible. When the underlying diagnosis is not obvious from the initial evaluation and review of medications, we assess HIV status and measure lymphocyte subpopulations (eg, CD4 count) and immunoglobulin levels. Additional testing for suspected primary immunodeficiency is described separately. (See  <a class="medical medical_review" href="/d/html/3903.html" rel="external">"Laboratory evaluation of the immune system"</a>.)</p><p>Examples of common findings and typical presentations are illustrated by the following:</p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 1042 hospitalized adults with an ALC &lt;600/microL in a teaching hospital, the most common causes for lymphocytopenia were as follows [<a href="#rid34">34</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bacterial or fungal sepsis – 24 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Postoperative state – 22 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Malignancy – 17 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Use of glucocorticoids – 15 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Cytotoxic chemotherapy and/or radiation therapy – 9 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Trauma or hemorrhage – 8 percent</p><p></p><p class="bulletIndent1">For the 698 patients in this study who had previous and subsequent blood counts, lymphocytopenia was persistently present in only 6 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with immunodeficiency due to primary or secondary immunodeficiency syndromes may present with a range of disorders, such as:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Recurrent infections</p><p class="bulletIndent2"><span class="glyph">•</span>Autoimmune disorders</p><p class="bulletIndent2"><span class="glyph">•</span>Inflammatory disorders (eg, inflammatory bowel disease, inflammatory arthritis)</p><p class="bulletIndent2"><span class="glyph">•</span>Malignancies (eg, lymphoma)</p><p class="bulletIndent2"><span class="glyph">•</span>Allergic disease (eg, atopic dermatitis, food allergy, allergic rhinosinusitis, asthma)</p><p></p><p class="bulletIndent1">Prospective cohort studies from Denmark that included more than 100,000 individuals reported an association between lymphocytopenia and mortality (1.6-fold); associations with cancer, cardiovascular disease, and infections were also identified [<a href="#rid35">35,36</a>]. Because of the nature of these studies, the causes of lymphocytopenia could not be ascertained.</p><p></p><p class="bulletIndent1">In addition to a reduction in the total number of circulating lymphocytes, a deficiency of one or more lymphocyte subsets may occur (eg, B cells, T cells, NK cells) and can be characteristic of a number of specific disorders. (See  <a class="medical medical_review" href="/d/html/3914.html" rel="external">"Primary humoral immunodeficiencies: An overview"</a> and  <a class="medical medical_review" href="/d/html/3935.html" rel="external">"Combined immunodeficiencies: An overview"</a> and  <a class="medical medical_review" href="/d/html/3955.html" rel="external">"Severe combined immunodeficiency (SCID): An overview"</a>.)</p><p></p><p class="headingAnchor" id="H330925285"><span class="h2">Management (lymphocytopenia)</span><span class="headingEndMark"> — </span>Management of lymphocytopenia depends on the underlying condition responsible and may include therapy related to associated cytopenias and/or other immune defects.</p><p>If the patient has an immunodeficiency syndrome associated with hypogammaglobulinemia, immunoglobulin replacement therapy may be administered. (See  <a class="medical medical_review" href="/d/html/3911.html" rel="external">"Immune globulin therapy in inborn errors of immunity"</a>.)</p><p>Hematopoietic cell transplantation (HCT) can be considered for patients with congenital immunodeficiencies and has curative potential in these patients. (See  <a class="medical medical_review" href="/d/html/3941.html" rel="external">"Hematopoietic cell transplantation for non-SCID inborn errors of immunity"</a>.)</p><p>In contrast, we generally do not intervene for patients with asymptomatic lymphocytopenia without an associated illness.</p><p class="headingAnchor" id="H330925315"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Lymphocytosis in adults is defined as an absolute lymphocyte count (ALC) &gt;4000 lymphocytes/microL. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes of lymphocytosis</strong> – A broad range of conditions can cause lymphocytosis (see <a class="local">'Causes of lymphocytosis'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Reactive/polyclonal</strong> – Infectious or non-infectious causes  (<a class="graphic graphic_table graphicRef58246" href="/d/graphic/58246.html" rel="external">table 2</a>).  </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clonal/malignant</strong> – Lymphoid malignancies and certain premalignant causes (eg, monoclonal B lymphocytosis). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial evaluation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical</strong> – History and examination should evaluate recent infections, constitutional symptoms (fevers, sweats, weight loss), lymphadenopathy, hepatosplenomegaly, medications, smoking, and comorbid illnesses.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Laboratory</strong> – Complete blood count (CBC) with differential count and review of blood smear should be performed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Urgency </strong>– Patients who are clinically unstable or have lymphoblasts on the blood smear should be evaluated promptly. For others, we generally repeat the CBC in two to four weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Further evaluation</strong> – The clinical setting and trajectory of ALC guide further evaluation:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Resolved/improved lymphocytosis </strong>– No further evaluation is needed for lymphocytosis that improves/resolves with observation. Examples include infectious mononucleosis, pertussis, other infections, and medications  (<a class="graphic graphic_table graphicRef58246" href="/d/graphic/58246.html" rel="external">table 2</a>). (See <a class="local">'Infectious causes'</a> above.)  </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Persistent/increasing</strong> <strong>lymphocytosis</strong> – For patients with persistent lymphocytosis, further evaluation is individualized. A decision to perform a diagnostic test (eg, flow cytometry, bone marrow [BM] examination) is guided by the level and trajectory of lymphocytosis, the clinical setting, and associated clinical findings. </p><p></p><p class="bulletIndent2">Examples of clinical scenarios include:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Suspected chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)</strong> – CLL/SLL should be suspected for patients with persistent lymphocytosis, lymphadenopathy, organomegaly, and smudge cells on blood smear  (<a class="graphic graphic_picture graphicRef96498" href="/d/graphic/96498.html" rel="external">picture 5</a>). Flow cytometry reveals co-expression of B cell markers and CD5 by the malignant lymphocytes. </p><p></p><p class="bulletIndent3">Further evaluation, diagnosis, and staging for CLL/SLL are described separately. (See  <a class="medical medical_review" href="/d/html/4513.html" rel="external">"Clinical features and diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Suspected acute leukemia </strong>– Acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL) should be suspected in patients with a rapidly rising ALC, unexplained cytopenias, progressive lymphadenopathy or organomegaly, and/or a mediastinal mass. </p><p></p><p class="bulletIndent3">Flow cytometry and BM examination should be performed urgently to evaluate an acute leukemia. Details of the evaluation and diagnosis of ALL/LBL are described separately. (See  <a class="medical medical_review" href="/d/html/4686.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of B cell acute lymphoblastic leukemia/lymphoma"</a> and  <a class="medical medical_review" href="/d/html/15773.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma"</a>.) and </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Large granular lymphocyte (LGL) disorders</strong> – LGLs on the blood smear, especially if associated with cytopenias and/or rheumatologic disorders, suggests a potential LGL disorder; flow cytometry is used to confirm the immunophenotype. Evaluation and diagnosis of LGL disorders are described separately. (See  <a class="medical medical_review" href="/d/html/16360.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of T cell large granular lymphocyte leukemia"</a>.) </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Isolated lymphocytosis/no other findings</strong> – For persistent lymphocytosis without lymphadenopathy or splenomegaly and no lymphoblasts on blood smear, we perform flow cytometry for clonality, immunophenotype, and quantitation of lymphocyte subsets. Possible diagnoses include early-stage CLL, monoclonal B cell lymphocytosis (MBL), and LGL leukemia. (See  <a class="medical medical_review" href="/d/html/118011.html" rel="external">"Monoclonal B cell lymphocytosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lymphocytopenia</strong> – Lymphocytopenia may be caused by drugs (eg, chemotherapy, immunosuppressive therapy), infections (eg, HIV), protein-energy undernutrition, systemic disease, congenital immunodeficiency disorders (eg, Wiskott-Aldrich syndrome, severe-combined immunodeficiency disorder), and other causes  (<a class="graphic graphic_table graphicRef58469" href="/d/graphic/58469.html" rel="external">table 3</a>). (See <a class="local">'Lymphocytopenia'</a> above.)</p><p></p><p class="headingAnchor" id="H4032127999"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>UpToDate acknowledges Nancy Berliner, MD who contributed to earlier versions of this topic review.</p><p>The editors of UpToDate acknowledge the contributions of Stanley L Schrier, MD as Section Editor on this topic, his tenure as the founding Editor-in-Chief for UpToDate in Hematology, and his dedicated and longstanding involvement with the UpToDate program.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Vetsika EK, Callan M. Infectious mononucleosis and Epstein-Barr virus. Expert Rev Mol Med 2004; 6:1.</a></li><li><a class="nounderline abstract_t">Heininger U, Stehr K, Schmitt-Grohé S, et al. Clinical characteristics of illness caused by Bordetella parapertussis compared with illness caused by Bordetella pertussis. Pediatr Infect Dis J 1994; 13:306.</a></li><li><a class="nounderline abstract_t">Kubic VL, Kubic PT, Brunning RD. The morphologic and immunophenotypic assessment of the lymphocytosis accompanying Bordetella pertussis infection. Am J Clin Pathol 1991; 95:809.</a></li><li class="breakAll">Margileth AM. Cat scratch disease. In: Nelson Textbook of Pediatrics, 15th ed, Behrman RE, Kliegman RM, Arvin AM (Eds), WB Saunders, Philadelphia 1996.</li><li><a class="nounderline abstract_t">Akcam FZ, Aygun FO, Akkaya VB. DRESS like severe drug rash with eosinophilia, atypic lymphocytosis and fever secondary to ceftriaxone. J Infect 2006; 53:e51.</a></li><li><a class="nounderline abstract_t">Teggatz JR, Parkin J, Peterson L. Transient atypical lymphocytosis in patients with emergency medical conditions. Arch Pathol Lab Med 1987; 111:712.</a></li><li><a class="nounderline abstract_t">Kho AN, Hui S, Kesterson JG, McDonald CJ. Which observations from the complete blood cell count predict mortality for hospitalized patients? J Hosp Med 2007; 2:5.</a></li><li><a class="nounderline abstract_t">Casassus P, Lortholary P, Komarover H, et al. Cigarette smoking-related persistent polyclonal B lymphocytosis. A premalignant state. Arch Pathol Lab Med 1987; 111:1081.</a></li><li><a class="nounderline abstract_t">Delannoy A, Djian D, Wallef G, et al. Cigarette smoking and chronic polyclonal B-cell lymphocytosis. Nouv Rev Fr Hematol 1993; 35:141.</a></li><li><a class="nounderline abstract_t">Troussard X, Mossafa H, Valensi F, et al. [Polyclonal lymphocytosis with binucleated lymphocytes. Morphological, immunological, cytogenetic and molecular analysis in 15 cases]. Presse Med 1997; 26:895.</a></li><li><a class="nounderline abstract_t">Lesesve JF, Troussard X. Persistent polyclonal B-cell lymphocytosis. Blood 2011; 118:6485.</a></li><li><a class="nounderline abstract_t">Troussard X, Cornet E, Lesesve JF, et al. Polyclonal B-cell lymphocytosis with binucleated lymphocytes (PPBL). Onco Targets Ther 2008; 1:59.</a></li><li><a class="nounderline abstract_t">Cornet E, Lesesve JF, Mossafa H, et al. Long-term follow-up of 111 patients with persistent polyclonal B-cell lymphocytosis with binucleated lymphocytes. Leukemia 2009; 23:419.</a></li><li><a class="nounderline abstract_t">Delage R, Roy J, Jacques L, Darveau A. All patients with persistent polyclonal B cell lymphocytosis present Bcl-2/Ig gene rearrangements. Leuk Lymphoma 1998; 31:567.</a></li><li><a class="nounderline abstract_t">Dasanu CA, Codreanu I. Persistent polyclonal B-cell lymphocytosis in chronic smokers: more than meets the eye. Conn Med 2012; 76:69.</a></li><li><a class="nounderline abstract_t">Loembé MM, Lamoureux J, Deslauriers N, et al. Lack of CD40-dependent B-cell proliferation in B lymphocytes isolated from patients with persistent polyclonal B-cell lymphocytosis. Br J Haematol 2001; 113:699.</a></li><li><a class="nounderline abstract_t">Himmelmann A, Gautschi O, Nawrath M, et al. Persistent polyclonal B-cell lymphocytosis is an expansion of functional IgD(+)CD27(+) memory B cells. Br J Haematol 2001; 114:400.</a></li><li><a class="nounderline abstract_t">Salcedo I, Campos-Caro A, Sampalo A, et al. Persistent polyclonal B lymphocytosis: an expansion of cells showing IgVH gene mutations and phenotypic features of normal lymphocytes from the CD27+ marginal zone B-cell compartment. Br J Haematol 2002; 116:662.</a></li><li><a class="nounderline abstract_t">Delage R, Jacques L, Massinga-Loembe M, et al. Persistent polyclonal B-cell lymphocytosis: further evidence for a genetic disorder associated with B-cell abnormalities. Br J Haematol 2001; 114:666.</a></li><li><a class="nounderline abstract_t">Juneja S, Januszewicz E, Wolf M, Cooper I. Post-splenectomy lymphocytosis. Clin Lab Haematol 1995; 17:335.</a></li><li><a class="nounderline abstract_t">Garcia-Suarez J, Prieto A, Reyes E, et al. Persistent lymphocytosis of natural killer cells in autoimmune thrombocytopenic purpura (ATP) patients after splenectomy. Br J Haematol 1995; 89:653.</a></li><li><a class="nounderline abstract_t">Doll DC, Landreneau RJ, List AF. Malignant thymoma associated with peripheral T-cell lymphocytosis. Med Pediatr Oncol 1991; 19:496.</a></li><li><a class="nounderline abstract_t">Barton AD. T-cell lymphocytosis associated with lymphocyte-rich thymoma. Cancer 1997; 80:1409.</a></li><li><a class="nounderline abstract_t">Cranney A, Markman S, Lach B, Karsh J. Polymyositis in a patient with thymoma and T cell lymphocytosis. J Rheumatol 1997; 24:1413.</a></li><li><a class="nounderline abstract_t">Otton SH, Standen GR, Ormerod IE. T cell lymphocytosis associated with polymyositis, myasthenia gravis and thymoma. Clin Lab Haematol 2000; 22:307.</a></li><li><a class="nounderline abstract_t">Snow AL, Xiao W, Stinson JR, et al. Congenital B cell lymphocytosis explained by novel germline CARD11 mutations. J Exp Med 2012; 209:2247.</a></li><li><a class="nounderline abstract_t">Bockorny B, Dasanu CA. Autoimmune manifestations in large granular lymphocyte leukemia. Clin Lymphoma Myeloma Leuk 2012; 12:400.</a></li><li><a class="nounderline abstract_t">Pontikoglou C, Kalpadakis C, Papadaki HA. Pathophysiologic mechanisms and management of neutropenia associated with large granular lymphocytic leukemia. Expert Rev Hematol 2011; 4:317.</a></li><li><a class="nounderline abstract_t">Liu X, Loughran TP Jr. The spectrum of large granular lymphocyte leukemia and Felty's syndrome. Curr Opin Hematol 2011; 18:254.</a></li><li><a class="nounderline abstract_t">Brady KA, Atwater SK, Lowell CA. Flow cytometric detection of CD10 (cALLA) on peripheral blood B lymphocytes of neonates. Br J Haematol 1999; 107:712.</a></li><li><a class="nounderline abstract_t">Chantepie SP, Salaün V, Parienti JJ, et al. Hematogones: a new prognostic factor for acute myeloblastic leukemia. Blood 2011; 117:1315.</a></li><li><a class="nounderline abstract_t">Sevilla DW, Colovai AI, Emmons FN, et al. Hematogones: a review and update. Leuk Lymphoma 2010; 51:10.</a></li><li><a class="nounderline abstract_t">Kanegane H, Yachie A, Miyawaki T, Tosato G. EBV-NK cells interactions and lymphoproliferative disorders. Leuk Lymphoma 1998; 29:491.</a></li><li><a class="nounderline abstract_t">Castelino DJ, McNair P, Kay TW. Lymphocytopenia in a hospital population--what does it signify? Aust N Z J Med 1997; 27:170.</a></li><li><a class="nounderline abstract_t">Warny M, Helby J, Nordestgaard BG, et al. Incidental lymphopenia and mortality: a prospective cohort study. CMAJ 2020; 192:E25.</a></li><li><a class="nounderline abstract_t">Warny M, Helby J, Nordestgaard BG, et al. Lymphopenia and risk of infection and infection-related death in 98,344 individuals from a prospective Danish population-based study. PLoS Med 2018; 15:e1002685.</a></li></ol></div><div id="topicVersionRevision">Topic 104124 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15541197" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Infectious mononucleosis and Epstein-Barr virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8036048" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Clinical characteristics of illness caused by Bordetella parapertussis compared with illness caused by Bordetella pertussis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2042590" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The morphologic and immunophenotypic assessment of the lymphocytosis accompanying Bordetella pertussis infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2042590" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The morphologic and immunophenotypic assessment of the lymphocytosis accompanying Bordetella pertussis infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16352341" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : DRESS like severe drug rash with eosinophilia, atypic lymphocytosis and fever secondary to ceftriaxone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3632284" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Transient atypical lymphocytosis in patients with emergency medical conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17274042" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Which observations from the complete blood cell count predict mortality for hospitalized patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3499130" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Cigarette smoking-related persistent polyclonal B lymphocytosis. A premalignant state.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8332450" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Cigarette smoking and chronic polyclonal B-cell lymphocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9232058" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : [Polyclonal lymphocytosis with binucleated lymphocytes. Morphological, immunological, cytogenetic and molecular analysis in 15 cases].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22279623" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Persistent polyclonal B-cell lymphocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21127753" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Polyclonal B-cell lymphocytosis with binucleated lymphocytes (PPBL).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18668130" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Long-term follow-up of 111 patients with persistent polyclonal B-cell lymphocytosis with binucleated lymphocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9922047" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : All patients with persistent polyclonal B cell lymphocytosis present Bcl-2/Ig gene rearrangements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22670354" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Persistent polyclonal B-cell lymphocytosis in chronic smokers: more than meets the eye.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11380461" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Lack of CD40-dependent B-cell proliferation in B lymphocytes isolated from patients with persistent polyclonal B-cell lymphocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11529864" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Persistent polyclonal B-cell lymphocytosis is an expansion of functional IgD(+)CD27(+) memory B cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11849229" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Persistent polyclonal B lymphocytosis: an expansion of cells showing IgVH gene mutations and phenotypic features of normal lymphocytes from the CD27+ marginal zone B-cell compartment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11552996" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Persistent polyclonal B-cell lymphocytosis: further evidence for a genetic disorder associated with B-cell abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8697729" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Post-splenectomy lymphocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7734372" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Persistent lymphocytosis of natural killer cells in autoimmune thrombocytopenic purpura (ATP) patients after splenectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1961136" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Malignant thymoma associated with peripheral T-cell lymphocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9338464" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : T-cell lymphocytosis associated with lymphocyte-rich thymoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9228147" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Polymyositis in a patient with thymoma and T cell lymphocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11122275" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : T cell lymphocytosis associated with polymyositis, myasthenia gravis and thymoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23129749" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Congenital B cell lymphocytosis explained by novel germline CARD11 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22999943" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Autoimmune manifestations in large granular lymphocyte leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21668396" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Pathophysiologic mechanisms and management of neutropenia associated with large granular lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21546829" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The spectrum of large granular lymphocyte leukemia and Felty's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10606874" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Flow cytometric detection of CD10 (cALLA) on peripheral blood B lymphocytes of neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21079153" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Hematogones: a new prognostic factor for acute myeloblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20001239" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Hematogones: a review and update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9643562" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : EBV-NK cells interactions and lymphoproliferative disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9145181" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Lymphocytopenia in a hospital population--what does it signify?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31932337" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Incidental lymphopenia and mortality: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30383787" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Lymphopenia and risk of infection and infection-related death in 98,344 individuals from a prospective Danish population-based study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
